Stock Research for ACST

ACST

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ACST Stock Chart & Research Data

The ACST chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ACST chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ACST Due diligence Resources & Stock Charts

The ACST stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ACST Detailed Price Forecast - CNN Money CNN View ACST Detailed Summary - Google Finance
Yahoo View ACST Detailed Summary - Yahoo! Finance Zacks View ACST Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ACST Trends & Analysis - Trade-Ideas Barrons View ACST Major Holders - Barrons
NASDAQ View ACST Call Transcripts - NASDAQ Seeking View ACST Breaking News & Analysis - Seeking Alpha
Spotlight View ACST Annual Report - CompanySpotlight.com OTC Report View ACST OTC Short Report - OTCShortReport.com
TradeKing View ACST Fundamentals - TradeKing Charts View ACST SEC Filings - Bar Chart
WSJ View Historical Prices for ACST - The WSJ Morningstar View Performance/Total Return for ACST - Morningstar
MarketWatch View the Analyst Estimates for ACST - MarketWatch CNBC View the Earnings History for ACST - CNBC
StockMarketWatch View the ACST Earnings - StockMarketWatch MacroAxis View ACST Buy or Sell Recommendations - MacroAxis
Bullish View the ACST Bullish Patterns - American Bulls Short Pains View ACST Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ACST Stock Mentions - StockTwits PennyStocks View ACST Stock Mentions - PennyStockTweets
Twitter View ACST Stock Mentions - Twitter Invest Hub View ACST Investment Forum News - Investor Hub
Yahoo View ACST Stock Mentions - Yahoo! Message Board Seeking Alpha View ACST Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ACST - SECform4.com Insider Cow View Insider Transactions for ACST - Insider Cow
CNBC View ACST Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ACST - OTC Markets
Yahoo View Insider Transactions for ACST - Yahoo! Finance NASDAQ View Institutional Holdings for ACST - NASDAQ


Stock Charts

FinViz View ACST Stock Insight & Charts - FinViz.com StockCharts View ACST Investment Charts - StockCharts.com
BarChart View ACST Stock Overview & Charts - BarChart Trading View View ACST User Generated Charts - Trading View




Latest Financial News for ACST


Acasti Pharma to Present at the 11th Annual LD Micro Main Event
Posted on Tuesday November 27, 2018

Laval, Québec / ACCESSWIRE / November 27, 2018 / Acasti Pharma Inc. (ACST) (ACST) (the "Company" or "Acasti Pharma"), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that the Company is scheduled to present at the 11th annual LD Micro Main Event on Wednesday, December 5 at 3:00 PM PST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Jan D'Alvise, President and Chief Executive Office, will be presenting, as well as meeting with investors.


Acasti: Fiscal 2Q Earnings Snapshot
Posted on Wednesday November 14, 2018

On a per-share basis, the Laval, Quebec-based company said it had a loss of 47 cents. Losses, adjusted for non-recurring costs and amortization costs, came to 19 cents per share. The company's shares closed ...


Acasti Pharma Provides Business Update for Second Quarter of Fiscal 2019
Posted on Wednesday November 14, 2018

LAVAL, Québec, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today provided a business update and announced its operating and financial results for the fiscal second quarter ended September 30, 2018. Jan D’Alvise, president and CEO of Acasti Pharma, commented, “Following our recent capital raises in the U.S. and Canada, I am pleased to report as of November 1, we had over $52 million of cash on hand.


Acasti Pharma Schedules Second Quarter Fiscal 2019 Conference Call
Posted on Wednesday November 07, 2018

Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST) (the “Company” or “Acasti”), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it will host a conference call at 11:00 AM Eastern Time on Wednesday, November 14, 2018 to discuss the Company’s financial results for the fiscal second quarter ended September 30, 2018, as well as the Company’s corporate progress and other developments. The conference call will be available via telephone by dialing toll free 877-407-8031 for U.S. callers or +1 201-689-8031 for international callers, or on the Company’s News and Investors section of the website: https://www.acastipharma.com/investors/.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.